Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.97 USD
−50.73 M USD
5.49 M USD
59.65 M
About Cue Biopharma, Inc.
Sector
Industry
CEO
Daniel R. Passeri
Website
Headquarters
Boston
Founded
2014
FIGI
BBG00FVMPFN7
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CUE is 1.63 USD — it has increased by 14.77% in the past 24 hours. Watch Cue Biopharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cue Biopharma, Inc. stocks are traded under the ticker CUE.
CUE stock has fallen by −2.29% compared to the previous week, the month change is a 98.84% rise, over the last year Cue Biopharma, Inc. has showed a −36.27% decrease.
We've gathered analysts' opinions on Cue Biopharma, Inc. future price: according to them, CUE price has a max estimate of 6.00 USD and a min estimate of 2.00 USD. Watch CUE chart and read a more detailed Cue Biopharma, Inc. stock forecast: see what analysts think of Cue Biopharma, Inc. and suggest that you do with its stocks.
CUE stock is 21.15% volatile and has beta coefficient of 0.31. Track Cue Biopharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cue Biopharma, Inc. there?
Today Cue Biopharma, Inc. has the market capitalization of 102.95 M, it has increased by 8.78% over the last week.
Yes, you can track Cue Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
Cue Biopharma, Inc. is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
CUE earnings for the last quarter are −0.20 USD per share, whereas the estimation was −0.28 USD resulting in a 28.57% surprise. The estimated earnings for the next quarter are −0.18 USD per share. See more details about Cue Biopharma, Inc. earnings.
Cue Biopharma, Inc. revenue for the last quarter amounts to 2.66 M USD, despite the estimated figure of 1.29 M USD. In the next quarter, revenue is expected to reach 1.52 M USD.
CUE net income for the last quarter is −10.17 M USD, while the quarter before that showed −12.35 M USD of net income which accounts for 17.62% change. Track more Cue Biopharma, Inc. financial stats to get the full picture.
No, CUE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 6, 2024, the company has 53.00 employees. See our rating of the largest employees — is Cue Biopharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cue Biopharma, Inc. EBITDA is −44.72 M USD, and current EBITDA margin is −884.44%. See more stats in Cue Biopharma, Inc. financial statements.
Like other stocks, CUE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cue Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cue Biopharma, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cue Biopharma, Inc. stock shows the sell signal. See more of Cue Biopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.